Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xenon Pharmaceuticals Inc (NQ: XENE ) 40.73 +1.03 (+2.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Xenon Pharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference October 02, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress September 09, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer August 12, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Earnings Scheduled For February 29, 2024 February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. Via Benzinga Earnings Outlook For Xenon Pharmaceuticals February 28, 2024 Via Benzinga 4 Analysts Have This to Say About Xenon Pharmaceuticals December 08, 2023 Via Benzinga XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 August 08, 2024 XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Xenon Reports Q2 2024 Financial Results and Business Update August 08, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon to Report Q2 2024 Financial Results on August 8, 2024 August 01, 2024 Conference Call and webcast scheduled at 4:30 pm ET From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting May 28, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 May 09, 2024 XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024 May 08, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update May 02, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting April 16, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 10, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference April 04, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days March 12, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 March 05, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 29, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update February 22, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire 3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition February 21, 2024 Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. Via InvestorPlace This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space February 16, 2024 Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... Via Benzinga Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 January 08, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares December 04, 2023 From Xenon Pharmaceuticals Inc. Via GlobeNewswire Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) December 02, 2023 From Xenon Pharmaceuticals Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.